Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin Extended Release for Hot Flashes in Postmenopausal Women
NCT00755417Phase 3Completed
- Sponsor
- Assertio
- Start
- Sep 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin in hot flashes (3 arms), sponsored by Assertio. Primary endpoints: Change From Baseline in Average Daily Frequency of Hot Flashes at 4 weeks and Change From Baseline in Average Daily Severity Score of Hot Flashes at 4 weeks. Started Sep 2008; status: completed.
02
Drugs
gabapentin
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT00755417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755417.